Literature DB >> 25941594

Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy.

Pedro R Lowenstein1, Gregory J Baker1, Maria G Castro1.   

Abstract

Natural killer (NK) cells eradicate galectin-deficient malignant gliomas without the necessity for T cell cooperation. This phenomenon was discovered as a consequence of reducing glioma-derived galectin-1. We propose that stimulation of endogenous antitumor NK cell activity may be achieved by reducing potent tumor-derived NK cell inhibitors, such as galectin-1, and that such agents be tested in the clinic to treatbrain tumors.

Entities:  

Keywords:  galectin-1; innate antitumor immunity; malignant glioma; natural killer cells

Year:  2014        PMID： 25941594      PMCID： PMC4292565          DOI： 10.4161/21624011.2014.965573

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Multiple functional targets of the immunoregulatory activity of galectin-1: Control of immune cell trafficking, dendritic cell physiology, and T-cell fate.

Authors:  Dianne Cooper; Juan M Ilarregui; Susana A Pesoa; Diego O Croci; Mauro Perretti; Gabriel A Rabinovich
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

Review 2.  Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme.

Authors:  Amade Bregy; Theresa M Wong; Ashish H Shah; John M Goldberg; Ricardo J Komotar
Journal:  Cancer Treat Rev       Date:  2013-06-21       Impact factor: 12.111

3.  Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients.

Authors:  Courtney A Crane; Kathryn Austgen; Kristen Haberthur; Carly Hofmann; Kara White Moyes; Lia Avanesyan; Lawrence Fong; Michael J Campbell; Stewart Cooper; Scott A Oakes; Andrew T Parsa; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

Review 4.  Controversies in the adjuvant therapy of high-grade gliomas.

Authors:  Matthias Holdhoff; Stuart A Grossman
Journal:  Oncologist       Date:  2011-02-21

5.  CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.

Authors:  Katherine A Murphy; Jami R Erickson; Charles S Johnson; Charles E Seiler; Jessica Bedi; Peisheng Hu; G Elizabeth Pluhar; Alan L Epstein; John R Ohlfest
Journal:  J Immunol       Date:  2013-11-29       Impact factor: 5.422

6.  Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.

Authors:  Gregory J Baker; Peter Chockley; Viveka Nand Yadav; Robert Doherty; Michael Ritt; Sivaraj Sivaramakrishnan; Maria G Castro; Pedro R Lowenstein
Journal:  Cancer Res       Date:  2014-07-18       Impact factor: 12.701

Review 7.  An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.

Authors:  David A Reardon; Kai W Wucherpfennig; Gordon Freeman; Catherine J Wu; E Antonio Chiocca; Patrick Y Wen; William T Curry; Duane A Mitchell; Peter E Fecci; John H Sampson; Glenn Dranoff
Journal:  Expert Rev Vaccines       Date:  2013-06       Impact factor: 5.217

8.  Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.

Authors:  Gregory J Baker; Viveka Nand Yadav; Sebastien Motsch; Carl Koschmann; Anda-Alexandra Calinescu; Yohei Mineharu; Sandra Ines Camelo-Piragua; Daniel Orringer; Serguei Bannykh; Wesley S Nichols; Ana C deCarvalho; Tom Mikkelsen; Maria G Castro; Pedro R Lowenstein
Journal:  Neoplasia       Date:  2014-07       Impact factor: 5.715

9.  Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion.

Authors:  L Gerard Toussaint; Allan E Nilson; Jennie M Goble; Karla V Ballman; C David James; Florence Lefranc; Robert Kiss; Joon H Uhm
Journal:  Mol Cancer       Date:  2012-05-14       Impact factor: 27.401

10.  HMGB1 mediates endogenous TLR2 activation and brain tumor regression.

Authors:  James F Curtin; Naiyou Liu; Marianela Candolfi; Weidong Xiong; Hikmat Assi; Kader Yagiz; Matthew R Edwards; Kathrin S Michelsen; Kurt M Kroeger; Chunyan Liu; A K M Ghulam Muhammad; Mary C Clark; Moshe Arditi; Begonya Comin-Anduix; Antoni Ribas; Pedro R Lowenstein; Maria G Castro
Journal:  PLoS Med       Date:  2009-01-13       Impact factor: 11.069
  10 in total
  2 in total

Review 1.  Natural killer cell awakening: unleash cancer-immunity cycle against glioblastoma.

Authors:  Minjie Wang; Zijie Zhou; Xuan Wang; Chaocai Zhang; Xiaobing Jiang
Journal:  Cell Death Dis       Date:  2022-07-08       Impact factor: 9.685

2.  Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy.

Authors:  Shang-Yu Chou; Shao-Lun Yen; Chao-Cheng Huang; Eng-Yen Huang
Journal:  BMC Cancer       Date:  2018-01-30       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.